Notification No. 45_2021 to exempt Covid19 vaccine from BCD

## Policy Analysis Report: Customs Duty Exemption on COVID-19 Vaccine Imports **1. Executive Summary:** This report analyzes a notification issued by the Ministry of Finance, Department of Revenue, Government of India, regarding a temporary exemption from customs duty on imported COVID-19 vaccines. The notification, G.S.R. 672(E), exempts COVID-19 vaccines (defined under Chapter 30 of the Customs Tariff Act, 1975) from the whole of the duty of customs. This exemption is effective from October 1st, 2021, and remains in force until December 31st, 2021. The core purpose is to reduce the financial burden associated with importing COVID-19 vaccines, likely to increase vaccine availability and accessibility within India during the specified period. **2. Introduction:** This report aims to provide a detailed overview and analysis of Notification No. 45/2021-Customs, G.S.R. 672(E), issued by the Ministry of Finance, Department of Revenue, Government of India, concerning customs duty exemptions on imported COVID-19 vaccines. The analysis is based solely on the information provided within the notification text. **3. Policy Overview:** * This is a *new* policy introducing a temporary customs duty exemption. * **Core Objective(s):** The core objective, as inferred from the text, is to exempt imported COVID-19 vaccines from customs duty to facilitate their import into India. The notification explicitly states the exemption is enacted as the Central Government deems it “necessary in the public interest so to do.” **4. Background and Rationale:** As a new policy, the notification likely addresses the need to reduce the cost of importing COVID-19 vaccines. This, in turn, suggests a broader goal of increasing vaccine availability and affordability for the Indian population. The notification’s timing (September 2021) likely reflects ongoing efforts to manage the COVID-19 pandemic and accelerate vaccination efforts. **5. Key Provisions / Changes:** Since this is a new policy, the key provisions are: * **Exemption:** Complete exemption from the whole of the duty of customs leviable on imported goods that fall under the specified description. * **Goods Covered:** The exemption applies specifically to "COVID19 vaccine" classified under Chapter 30 of the Customs Tariff Act, 1975. * **Validity Period:** The exemption is temporary, valid from October 1st, 2021, to December 31st, 2021 (inclusive). **6. Target Audience and Stakeholders:** Based on the text, the directly affected stakeholders are: * **Vaccine Importers:** Companies or organizations involved in importing COVID-19 vaccines into India. * **Customs Authorities:** The customs department will be responsible for implementing the exemption. * **Ultimately, Indian Citizens:** The goal is likely to improve access to vaccines, indirectly benefiting the entire population. **7. Implementation Aspects (Inferred):** * **Responsible Agency:** The Ministry of Finance, Department of Revenue, through the Central Board of Indirect Taxes and Customs (CBIC). * **Timelines:** The policy specifies a clear start date (October 1st, 2021) and end date (December 31st, 2021) for the exemption. * **Procedure:** Importers will need to claim the exemption while complying with the Customs Act, 1962, and the Customs Tariff Act, 1975. Documentation and processes defined by the customs department will be necessary. **8. Expected Outcomes / Impact of Changes:** The likely intended outcomes are: * **Reduced Import Costs:** Lower financial burden for companies importing COVID-19 vaccines. * **Increased Vaccine Availability:** Potentially increased supply of vaccines within India due to lower import costs. * **Enhanced Vaccination Efforts:** Contributing to the government's vaccination program by making vaccines more accessible. * **Positive Impact on Public Health:** Supporting the control and mitigation of the COVID-19 pandemic. **9. Conclusion:** Notification No. 45/2021-Customs provides a temporary customs duty exemption on imported COVID-19 vaccines. This measure aims to reduce import costs, increase vaccine availability, and support ongoing vaccination efforts in India. The policy is significant for vaccine importers and the broader public health landscape, contributing to the government's strategy to combat the COVID-19 pandemic. Its short duration highlights the likely specific need for increased supply within that timeframe.

Key Entities Referenced